Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Psoriasis

Therapeutic area intelligence for Psoriasis with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 10
Catalysts: 0
Companies: 2

Companies

Hangzhou Zhongmei Huadong Pharmaceutical →

JNJ-77242113 →

Assets

Recent signals(10)

August 8, 2026

JNJ-77242113 Study Initiated for Moderate to Severe Plaque Psoriasis

A clinical trial has been initiated to evaluate the efficacy of JNJ-77242113 in treating moderate to severe plaque psoriasis.

RegulatoryJuly 28, 2026

FDA Submission Status Update for Calcipotriene by Glenmark

The FDA has accepted the ANDA submission for Calcipotriene by Glenmark, indicating progress in the regulatory review process.

RegulatoryJuly 13, 2026

FDA Accepts Supplement Application for Brodalumab (Siliq) by Valeant

The FDA has accepted a supplemental application for Brodalumab (Siliq) submitted by Valeant Luxembourg.

ClinicalJuly 12, 2026

Efficacy of IL-17 Inhibitors After IL-23 Failure in Psoriasis Patients

Data on the efficacy and drug survival of IL-17 inhibitors after IL-23 inhibitor failure in psoriasis patients is limited.

RegulatoryJuly 8, 2026

FDA Accepts Supplemental NDA for Sotyktu (Deucravacitinib) by Bristol

The FDA has accepted a supplemental NDA for Sotyktu (Deucravacitinib) submitted by Bristol.

ClinicalJuly 7, 2026

Phase 3 Study of Roflumilast Cream 0.3% Shows Promise for Plaque Psoriasis

A Phase 3 study is underway to assess the efficacy and safety of roflumilast cream 0.3% in patients with plaque psoriasis.

RegulatoryJuly 4, 2026

FDA Acceptance of Calcipotriene Supplement by Glenmark

The FDA has accepted the supplement application ANDA205772 for Calcipotriene submitted by Glenmark.

ClinicalJuly 4, 2026

Study on Psoriasis and Cardiometabolic Disease Relationship Launched by NHLBI

The NHLBI has initiated a study to explore the relationship between psoriasis and cardiometabolic diseases.

ClinicalJune 26, 2026

Janssen's Guselkumab Trial Targets Skin of Color Patients with Psoriasis

A clinical trial is underway to assess the efficacy of guselkumab in skin of color participants with moderate-to-severe psoriasis.

ClinicalJune 24, 2026

Phase III Trial of MC2-01 Cream for Plaque Psoriasis Shows Efficacy and Safety

A Phase III trial is underway to evaluate the efficacy and safety of MC2-01 cream compared to existing treatments in plaque psoriasis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.